| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015.CA Cancer J Clin, 2015, 65(1): 5-29.
|
| [2] |
Knosel T, Petersen S, Schwabe H, et al.Incidence of chromaosomal imablance in advanced colorectal carcinomas and their metastases.Virchows Arch, 2002, 440: 187-194.
|
| [3] |
De Angelis PM, Clausen OP, Schjolberg A, et al.Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and ph enotypes.Br J Cancer, 1999, 80: 526-535.
|
| [4] |
De Aangelis PM, Stokke T, Beigi M, et al.Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer.Int J Colorectal Dis, 2001, 16: 38-45.
|
| [5] |
Aaltonen LA, Peltomaki P, Mecklin JP, et al.Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients.Cancer Res, 1994, 54: 1645-1648.
|
| [6] |
Chung DC, Rustgi AK.The hereditaty nonpolyposis colorectal cancer syndrome: genetic and clinical implcations.Ann Ietern Med, 2003, 138: 560-570.
|
| [7] |
Kastrinos F, Syngal S. Recently identified colon cancer predispositions: MYH and MSH6 mutations.Semin Oncol, 2007, 34(3): 418-424.
|
| [8] |
Miyakura Y, Sugano K, Akasu T, et al.Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability.Clin Gastroenterol Hepatol, 2004, 2: 147-156.
|
| [9] |
Herman JG, Baylin SB.Gene silence in cancer in association with promote hypermethylation.N Eengl J Med, 2003, 349: 2042-2054.
|
| [10] |
Gurzu S, Szentirmay Z, Popa D, et al.Practical value of the new system for Maspin assessment, in colorectal cancer.Neoplasma, 2013, 60(4): 373-383.
|
| [11] |
Turaga K, Shibata D. K-Ras and MSI: potential markers of both patient prognosis and treatment efficacy.Ann Surg Oncol, 2010, 17(2): 354-355.
|
| [12] |
Toyota M, Ahuja N, Ohe-Toyota M. CpG island methylator phenotype in colorectal cancer.Proc Natl Acad Sci, USA, 1999, 96: 8681-8686.
|
| [13] |
Van Rijnsoever M, Elsaleh H, Joseph D, et al.CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.Clin Cancer Res, 2003, 9: 2898-2903.
|
| [14] |
Shen L, Catalano PJ, Benson AB, et al.Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.Clin Cancer Res, 2007, 13(3): 6093-6098.
|
| [15] |
Linnekamp JF, Wang X, Medema JP, et al.Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.Cancer Res, 2015, 75(2): 245-249.
|
| [16] |
Stefanius K, Ylitalo L, Tuomisto A, et al.Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma.Histopathology, 2011, 58(5): 679-692.
|
| [17] |
Gurzu S, Szentirmay Z, Toth E, et al.Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition.PLOS One, 2013, 8(3): e57699.
|
| [18] |
Sanchez A, Krumroy, Plummer.Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.Br J Surg, 2009, 96(10): 1196-1204.
|
| [19] |
Yothers G, O’Connell MJ, Lee M, et al.Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin(FU/LV)and FU/LV plus oxaliplatin.J Clin Oncol, 2013, 31: 4512-4519.
|
| [20] |
Niedzwiecki D, Frankel W, Venook AP, et al.Association between ColDx assay result and recurrence-free interval in stage II colon cancer patientsonCALGB(Alliance)9581.J Clin Oncol, 2014, 32(3): 455.
|
| [21] |
Salazar R, Capdevila J, Rosenberg R, et al.Comparison of ColoPrint risk classification with clinical risk in the prospective PARS Ctrial.J Clin Oncol, 2014, 32(3): 465.
|
| [22] |
Cancer Genome Atlas Network.Comprehensive molecular characterization of human colon and rectal cancer.Nature, 2012, 487: 330-337.
|
| [23] |
De Sousa E, Wang X, Jansen M, et al.Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions.Nature Med, 2013, 19: 614-618.
|
| [24] |
Sadanandam A, Lyssiotis CA, Homicsko K, et al.A colorectal cancer classification system that associates cellular phenotype and responses to therapy.Nature Med, 2013, 19: 619-625.
|
| [25] |
Marisa L, de Reynies A, Duval A, et al.Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value.PLOS Med, 2013, 10: e1001453.
|
| [26] |
Roepman P, Schlicker A, Tabernero J, et al.Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.Int J Cancer, 2014, 134: 552-562.
|